The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
Mac Lochlainn, Dylan J
The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. [electronic resource] - Molecular genetics and metabolism 02 2018 - 154-158 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1096-7206
10.1016/j.ymgme.2017.10.001 doi
Adult
Double-Blind Method
Enzyme Replacement Therapy
Fabry Disease--enzymology
Humans
Isoenzymes--administration & dosage
Male
Middle Aged
Predictive Value of Tests
Recombinant Proteins--administration & dosage
Retrospective Studies
Severity of Illness Index
alpha-Galactosidase--administration & dosage
The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. [electronic resource] - Molecular genetics and metabolism 02 2018 - 154-158 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1096-7206
10.1016/j.ymgme.2017.10.001 doi
Adult
Double-Blind Method
Enzyme Replacement Therapy
Fabry Disease--enzymology
Humans
Isoenzymes--administration & dosage
Male
Middle Aged
Predictive Value of Tests
Recombinant Proteins--administration & dosage
Retrospective Studies
Severity of Illness Index
alpha-Galactosidase--administration & dosage